IN VITRO AND IN VIVO INTERACTIONS BETWEEN THE HDAC6 INHIBITOR RICOLINOSTAT (ACY1215) AND THE IRREVERSIBLE PROTEASOME INHIBITOR CARFILZOMIB IN NON-HODGKIN’S LYMPHOMA CELLS

Interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor Carfilzomib (CFZ) were examined in non-Hodgkin’s lymphoma models, including diffuse large B-cell (DLBCL), mantle cell (MCL) and double-hit lymphoma cells. Marked in vitro synergism was observed...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Autores principales: Dasmahapatra, Girija, Patel, Hiral, Friedberg, Johnathan, Quayle, Steven N, Jones, Simon S, Grant, Steven
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4304772/
https://ncbi.nlm.nih.gov/pubmed/25239935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0220
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares